Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1995 Sep;50(Suppl 1):S5–10. doi: 10.1136/thx.50.suppl_1.s5

Asthma and the beta agonist debate.

J Crane 1, N Pearce 1, C Burgess 1, R Beasley 1
PMCID: PMC1129009  PMID: 7570465

Full text

PDF
S5

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beasley R., Burgess C., Pearce N., Woodman K., Crane J. Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy. 1994 Jul;24(7):660–668. doi: 10.1111/j.1365-2222.1994.tb00970.x. [DOI] [PubMed] [Google Scholar]
  2. Beasley R., Pearce N., Crane J., Windom H., Burgess C. Asthma mortality and inhaled beta agonist therapy. Aust N Z J Med. 1991 Oct;21(5):753–763. doi: 10.1111/j.1445-5994.1991.tb01385.x. [DOI] [PubMed] [Google Scholar]
  3. Blauw G. J., Westendorp R. G. Asthma deaths in New Zealand: whodunnit? Lancet. 1995 Jan 7;345(8941):2–3. doi: 10.1016/s0140-6736(95)91143-x. [DOI] [PubMed] [Google Scholar]
  4. Chapman K. R., Kesten S., Szalai J. P. Regular vs as-needed inhaled salbutamol in asthma control. Lancet. 1994 Jun 4;343(8910):1379–1382. doi: 10.1016/s0140-6736(94)92520-8. [DOI] [PubMed] [Google Scholar]
  5. Collins J. M., McDevitt D. G., Shanks R. G., Swanton J. G. The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol. 1969 May;36(1):35–45. doi: 10.1111/j.1476-5381.1969.tb08301.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  7. Ernst P., Habbick B., Suissa S., Hemmelgarn B., Cockcroft D., Buist A. S., Horwitz R. I., McNutt M., Spitzer W. O. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis. 1993 Jul;148(1):75–79. doi: 10.1164/ajrccm/148.1.75. [DOI] [PubMed] [Google Scholar]
  8. Grainger J., Woodman K., Pearce N., Crane J., Burgess C., Keane A., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax. 1991 Feb;46(2):105–111. doi: 10.1136/thx.46.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grant I. W. Fenoterol and asthma deaths in New Zealand. N Z Med J. 1990 Apr 11;103(887):160–161. [PubMed] [Google Scholar]
  10. Hensley M. J. Fenoterol and death from asthma. Med J Aust. 1992 Jun 15;156(12):882–882. doi: 10.5694/j.1326-5377.1992.tb137010.x. [DOI] [PubMed] [Google Scholar]
  11. Horwitz R. I., Spitzer W., Buist S., Cockcroft D., Ernst P., Habbick B., Hemmelgarn B., McNutt M., Rebuck A. S., Suissa S. Clinical complexity and epidemiologic uncertainty in case-control research. Fenoterol and asthma management. Chest. 1991 Dec;100(6):1586–1591. doi: 10.1378/chest.100.6.1586. [DOI] [PubMed] [Google Scholar]
  12. Jackson R., Sears M. R., Beaglehole R., Rea H. H. International trends in asthma mortality: 1970 to 1985. Chest. 1988 Nov;94(5):914–918. doi: 10.1378/chest.94.5.914. [DOI] [PubMed] [Google Scholar]
  13. LOCKETT M. F. DANGEROUS EFFECTS OF ISOPRENALINE IN MYOCARDIAL FAILURE. Lancet. 1965 Jul 17;2(7403):104–106. doi: 10.1016/s0140-6736(65)92221-x. [DOI] [PubMed] [Google Scholar]
  14. Mullen M., Mullen B., Carey M. The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA. 1993 Oct 20;270(15):1842–1845. [PubMed] [Google Scholar]
  15. Pack R. J., Alley M. R., Dallimore J. A., Lapwood K. R., Burgess C., Crane J. The myocardial effects of fenoterol, isoprenaline and salbutamol in normoxic and hypoxic sheep. Int J Exp Pathol. 1994 Oct;75(5):357–362. [PMC free article] [PubMed] [Google Scholar]
  16. Pearce N., Beasley R., Crane J., Burgess C., Jackson R. End of the New Zealand asthma mortality epidemic. Lancet. 1995 Jan 7;345(8941):41–44. doi: 10.1016/s0140-6736(95)91159-6. [DOI] [PubMed] [Google Scholar]
  17. Pearce N., Crane J., Burgess C., Beasley R. Beta-agonist use and death from asthma. JAMA. 1994 Mar 16;271(11):822–823. [PubMed] [Google Scholar]
  18. Pearce N., Crane J., Burgess C., Beasley R., Jackson R. Beta-agonists and death from asthma. N Engl J Med. 1992 Jul 30;327(5):355–357. [PubMed] [Google Scholar]
  19. Pearce N., Crane J., Burgess C., Jackson R., Beasley R. Beta agonists and asthma mortality: déjà vu. Clin Exp Allergy. 1991 Jul;21(4):401–410. doi: 10.1111/j.1365-2222.1991.tb01679.x. [DOI] [PubMed] [Google Scholar]
  20. Pearce N., Grainger J., Atkinson M., Crane J., Burgess C., Culling C., Windom H., Beasley R. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990 Mar;45(3):170–175. doi: 10.1136/thx.45.3.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  22. Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
  23. Stolley P. D. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis. 1972 Jun;105(6):883–890. doi: 10.1164/arrd.1972.105.6.883. [DOI] [PubMed] [Google Scholar]
  24. Suissa S., Ernst P., Boivin J. F., Horwitz R. I., Habbick B., Cockroft D., Blais L., McNutt M., Buist A. S., Spitzer W. O. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):604–610. doi: 10.1164/ajrccm.149.3.8118625. [DOI] [PubMed] [Google Scholar]
  25. Tattersfield A. E. Use of beta 2 agonists in asthma: much ado about nothing? Still cause for concern. BMJ. 1994 Sep 24;309(6957):794–795. doi: 10.1136/bmj.309.6957.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Taylor D. R., Sears M. R. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest. 1994 Aug;106(2):552–559. doi: 10.1378/chest.106.2.552. [DOI] [PubMed] [Google Scholar]
  27. Trembath P. W., Greenacre J. K., Anderson M., Dimmock S., Mansfield L., Wadsworth J., Green M. Comparison of four weeks' treatment with fenoterol and terbutaline aerosols in adult asthmatics. A double-blind crossover study. J Allergy Clin Immunol. 1979 Jun;63(6):395–400. doi: 10.1016/0091-6749(79)90212-4. [DOI] [PubMed] [Google Scholar]
  28. Woodman K., Pearce N., Beasley R., Burgess C., Crane J. Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study. Clin Pharmacol Ther. 1992 May;51(5):566–571. doi: 10.1038/clpt.1992.64. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES